61477-94-9C[C@@H]1CCC[C@H](C)N1CCCC(O)(c1ccccc1)c1ccccn1.ClHFIHPVIVQSWZBV-ROSXHPEZSA-NSee also: Pirmenol (has active moiety).
61477-94-9DTXSID6021169CHEMBL1204211Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade.
DescriptionPirrnenol hydrochloride is a long-lasting Class la antiarrhythmic agent introduced in Japan in 1994. The spectrum of antiarrhythmic activity of pirmenol includes atrial and ventricular arrhythmias of diverse etiology. In clinical trials, pirmenol was found effective in the short- and mid-term treatment of chronic premature ventricular beats, with or without underlying heart disease. In patients with supraventricular tachycardia, a single oral dose of pirmenol was highly effective in suppressing induction of tachycardia with adequate hemodynamic tolerance. Since pirmenol is highly effective by both intravenous and oral routes, it enables immediate suppression, prevention, or termination of cardiac arrhythmias and facilitates the transition to oral prophylactic therapy.
UsesCardiac depressant (anti-arrhythmic).
No reaction records under the current filter.
Loading…